As the demand for affordable healthcare options grows, the pharmaceutical industry is increasingly focused on developing generic drugs to expand access and reduce costs. This trend is driving major ...

Teva's generic Saxenda is the first generic GLP-1 indicated for weight loss. Richardsen added, “This is the fifth first-to-market entry of a Teva generic this year and is an important addition to Teva ...

From Nike to adidas and Porsche to Gap, designer and artist Sean Wotherspoon has certainly imprinted his stamp on the sneaker and lifestyle industries. The innovative collaborator has now returned to ...

Teva is transforming, with management delivering on profit growth, specialty drug expansion, and improving its balance sheet—yet the stock remains undervalued. Specialty products like AUSTEDO and ...

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reported its second-quarter 2025 financial results on Wednesday, reflecting a mixed performance amid continued shifts in its portfolio strategy. The ...

Teva Pharmaceutical Industries Limited’s TEVA stock has risen 12.9% in a month. Teva’s stock mainly gained after it announced first-quarter 2025 results on May 7. Teva’s first-quarter results were ...

A recommendation upgrade from a veteran investment bank put some real zip in the shares. The analyst behind the change is now bullish on Teva's future. The person behind the modification was JPMorgan ...

With Teva entering the next stage of its sweeping restructuring plan, thousands of employees are slated to be let go from the hybrid generics and innovative medicines giant. As part of a new bid to ...

When is the best time to buy a new water heater? Hint: It’s not when the one you have fails. But that’s what many homeowners end up doing. They notice a leak—or worse, they’re surprised by a flood—and ...

This week, Teva launched its most ambitious global campaign in years, ‘For Playground Earth,’ a fully integrated marketing push that reaffirms its heritage in outdoor adventure while inviting a new ...

Teva's Q4 earnings reveal significant headwinds, including declining U.S. generics revenue and rising costs in the API business, impacting overall profitability. Branded drugs like Austedo and Uzedy ...